Denali Therapeutics Inc.

DNLI

$19.73

Name : Denali Therapeutics Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $3,162,532,352.00

EPSttm : -1.72

Denali Therapeutics Inc.

$19.73

0.60%

$0.12

DNLI — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

10.31

Margin Of Safety %

Put/Call OI Ratio

1.75

EPS Next Q Diff

0.01

EPS Last/This Y

0.76

EPS This/Next Y

-0.07

Price

19.84

Target Price

36.19

Analyst Recom

1.15

Performance Q

-21.45

Upside

-214.0%

Beta

1.07

Ticker: DNLI

22 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-10-12	DNLI	18.95	1.30	2.39	12115
2026-10-13	DNLI	18.4	1.31	26.45	12247
2026-10-14	DNLI	17.79	1.30	77.50	12278
2026-10-15	DNLI	18.33	1.32	4.64	12391
2026-10-16	DNLI	17.53	1.34	11.50	12523
2026-10-19	DNLI	17.96	1.63	0.88	11659
2026-10-20	DNLI	18.94	1.50	0.67	12192
2026-10-21	DNLI	18.68	1.40	3.67	12648
2026-10-22	DNLI	18.67	1.44	1.41	12815
2026-10-23	DNLI	18.4	1.44	26.52	12965
2026-10-26	DNLI	18.67	1.43	32.63	12995
2026-10-27	DNLI	19.22	1.44	30.45	13091
2026-10-28	DNLI	19.28	1.46	16.40	13163
2026-10-29	DNLI	19.34	1.48	137.82	13279
2026-10-30	DNLI	18.94	1.52	9.75	13518
2026-11-02	DNLI	18.86	1.56	44.50	13754
2026-11-03	DNLI	19.49	1.58	39.30	13860
2026-11-04	DNLI	20.95	1.62	16.86	14360
2026-11-05	DNLI	19.71	1.68	29.32	14435
2026-11-06	DNLI	20.05	1.67	31.46	14413
2026-11-09	DNLI	20.34	1.71	2.96	14688
2026-11-10	DNLI	19.84	1.75	2.68	14893
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-10-12	DNLI	18.96	50.6	-	-2.22
2026-10-13	DNLI	18.40	50.6	-	-2.22
2026-10-14	DNLI	17.85	50.6	-	-2.22
2026-10-15	DNLI	18.33	50.6	-	-2.22
2026-10-16	DNLI	17.61	50.5	-	-2.22
2026-10-19	DNLI	18.04	50.5	-	-2.22
2026-10-20	DNLI	18.04	50.5	-	-2.22
2026-10-21	DNLI	18.93	50.5	-	-2.23
2026-10-22	DNLI	18.68	50.5	-	-2.23
2026-10-23	DNLI	18.41	50.5	-	-2.23
2026-10-26	DNLI	18.67	50.5	-	-2.23
2026-10-27	DNLI	19.22	50.5	-	-2.23
2026-10-28	DNLI	19.29	50.5	-	-2.23
2026-10-29	DNLI	19.33	50.5	-	-2.23
2026-10-30	DNLI	18.94	50.5	-	-2.23
2026-11-02	DNLI	18.86	50.5	-	-2.23
2026-11-03	DNLI	19.49	50.5	-	-2.23
2026-11-04	DNLI	20.94	50.5	-	-2.23
2026-11-05	DNLI	19.72	50.5	-	-2.23
2026-11-06	DNLI	20.06	22.3	-	-2.05
2026-11-09	DNLI	20.35	22.3	-	-2.05
2026-11-10	DNLI	19.84	15.7	-	-2.21
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-10-12	DNLI	-0.18	2.31	10.33
2026-10-13	DNLI	-0.18	2.31	10.33
2026-10-14	DNLI	-0.18	2.31	10.33
2026-10-15	DNLI	-0.18	2.31	10.33
2026-10-16	DNLI	-0.18	2.31	10.33
2026-10-19	DNLI	-0.18	2.32	10.33
2026-10-20	DNLI	-0.18	2.32	10.33
2026-10-21	DNLI	-0.18	2.32	10.33
2026-10-22	DNLI	-0.18	2.32	10.33
2026-10-23	DNLI	-0.18	2.32	10.33
2026-10-26	DNLI	-0.18	2.36	10.33
2026-10-27	DNLI	-0.18	2.36	10.34
2026-10-28	DNLI	-0.18	2.36	10.34
2026-10-29	DNLI	-0.18	2.36	10.34
2026-10-30	DNLI	-0.18	2.36	10.34
2026-11-02	DNLI	-0.18	2.27	10.34
2026-11-03	DNLI	-0.18	2.27	10.34
2026-11-05	DNLI	-0.18	2.27	10.34
2026-11-06	DNLI	-0.18	2.27	10.34
2026-11-09	DNLI	-0.18	1.50	10.31
2026-11-10	DNLI	-0.18	1.50	10.31
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-0.64

Avg. EPS Est. Current Quarter

-0.62

Avg. EPS Est. Next Quarter

-0.64

Insider Transactions

-0.18

Institutional Transactions

1.5

Beta

1.07

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

63.2

Max Drawdown 5-Year %

-78.3

Target Price

36.19

P/E

Forward P/E

PEG

P/S

148.82

P/B

3.43

P/Free Cash Flow

EPS

-1.74

Average EPS Est. Cur. Y

-2.21

EPS Next Y. (Est.)

-2.28

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-1470.5

Relative Volume

0.6

Return on Equity vs Sector %

-60.2

Return on Equity vs Industry %

-40.5

EPS 1 7Days Diff

EPS 1 30Days Diff

0.01

EBIT Estimation

◆ DNLI Healthcare

$19.85

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

10/20

Pullback

5/25

Volume

9/15

Valuation

12/20

TP/AR

3/10

Options

2/10

RSI

51.9

Range 1M

52.1%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

3/25

Growth

15/30

Estimates

2/20

Inst/Vol

4/15

Options

3/10

EPS Yr

41%

EPS NY

-28.8%

52W%

38.7%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +82.3% upside

Quality

4/30

Valuation

16/30

Growth

12/25

Stability

9/10

LT Trend

3/5

Upside

+82.3%

Quality

DNLI — P/E HistoricalBiotechnology

Denali Therapeutics Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 503

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

DNLI

Latest News

—

Caricamento notizie per DNLI…

stock quote shares DNLI – Denali Therapeutics Inc. Stock Price stock today

news today DNLI – Denali Therapeutics Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch DNLI – Denali Therapeutics Inc. yahoo finance google finance

stock history DNLI – Denali Therapeutics Inc. invest stock market

stock prices DNLI premarket after hours

ticker DNLI fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: DNLI

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y